| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes.
|
Nature
|
2007
|
10.21
|
|
2
|
Crystal structures of human SIRT3 displaying substrate-induced conformational changes.
|
J Biol Chem
|
2009
|
1.60
|
|
3
|
A protein deacetylase SIRT1 is a negative regulator of metalloproteinase-9.
|
FASEB J
|
2009
|
1.47
|
|
4
|
Biochemical characterization, localization, and tissue distribution of the longer form of mouse SIRT3.
|
Protein Sci
|
2009
|
1.46
|
|
5
|
Discovery of 4-amino-5,6-biaryl-furo[2,3-d]pyrimidines as inhibitors of Lck: development of an expedient and divergent synthetic route and preliminary SAR.
|
Bioorg Med Chem Lett
|
2007
|
0.98
|
|
6
|
Discovery of aminoquinazolines as potent, orally bioavailable inhibitors of Lck: synthesis, SAR, and in vivo anti-inflammatory activity.
|
J Med Chem
|
2006
|
0.97
|
|
7
|
Discovery of imidazo[1,2-b]thiazole derivatives as novel SIRT1 activators.
|
J Med Chem
|
2009
|
0.86
|
|
8
|
Discovery of novel 2,3-diarylfuro[2,3-b]pyridin-4-amines as potent and selective inhibitors of Lck: synthesis, SAR, and pharmacokinetic properties.
|
Bioorg Med Chem Lett
|
2007
|
0.80
|
|
9
|
Structure-guided design of aminopyrimidine amides as potent, selective inhibitors of lymphocyte specific kinase: synthesis, structure-activity relationships, and inhibition of in vivo T cell activation.
|
J Med Chem
|
2008
|
0.75
|